Sector News

Sanofi to sell anti-inflammatory drug portfolio to Fidia Farmaceutici

March 27, 2021
Life sciences

Sanofi has concluded an agreement to sell its anti-inflammatory drugs portfolio to Italian company Fidia Farmaceutici to streamline established products.

The latest deal continues the company’s strategic transformation by simplifying its portfolio.

Sanofi General Medicines executive vice-president Olivier Charmeil said: “Established Products is an important growth driver for Sanofi. However, we are re-focusing our efforts as part of the company’s overall strategic transformation in order to pioneer new opportunities that will drive strong health outcomes for the millions of lives we touch.

“Upon completion of appropriate regulatory processes, today’s agreement with Fidia Farmaceutici will ensure patients will have continued access to these seven brands while also allowing for us to further optimise our operating model through our play-to-win strategy.”

The divestment covers registrations, trademarks and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and emergent markets.

Sanofi noted that the products are currently used for treating a wide range of conditions in several therapeutic areas.

Fidia Farmaceutici president and CEO Carlo Pizzocaro said: “The acquisition confirms our will, despite the tough challenge created by Covid-19, to continue investing in core pharmaceutical business as part of our international growth, not only thanks to consolidation in the areas in which we are leaders but also through more solid positioning as a result of entering different therapeutic areas.”

The companies will not divulge the commercial terms of the agreement.

In January, Sanofi signed an agreement to acquire clinical-stage biopharmaceutical company Kymab for an upfront cash payment of about $1.1bn.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).